Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

SAN FRANCISCO, CA USA (UroToday.com) - This abstract was presented by Dr. Uemura and colleagues from Japan. This group reported on a randomized phase II trial to evaluate the efficacy of peptide vaccination therapy for chemotherapy-naive CRPC patients.

The primary endpoint of their study was progression-free survival, including serum PSA, with secondary endpoint being overall survival and safety. Early-stage CRPC (PSA< 10ng/ml) patients positive for HLA-A02 or A24 or A3 super family were randomized into 2 treatment groups -- peptide vaccine with low dose (1mg/day) dexamethasone (Dx) versus low dose Dx alone. Patients were vaccinated subcutaneously with 3 mg of selected peptides (max. 4 kinds) 6 times at 2-week intervals. Dx 1mg/day p.o. was started on the first day of peptide vaccination. Toxicity was assessed monthly, and immunological responses such as cytotoxic T-lymphocyte activity and clinical responses were evaluated every 3 months.

gucancerssympalt thumbA total of 83 chemotherapy-naive CRPC patients were enrolled into the trial. Of these, 10 patients were excluded due to HLA type mismatch and exclusion criteria. Seventy-three patients were then randomized (37 in the vaccine treatment group and 36 in the Dx group). They reported a median time of 602 days to PSA failure in the vaccine group vs 210 days in the controlled arm (p < 0.001). They concluded that combination therapy of peptide vaccines and low dose dexamethasone may be a promising tool for chemotherapy-naive CRPC patients.

Highlights of a presentation by Hirotsugu Uemura at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Department of Urology, Kinki University Faculty of Medicine, Osaka, Japan

Written by Reza Mehrazin, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting